Post-covid-19 neurological syndromes

Cover Page

Cite item

Full Text

Abstract

The article highlights the pathogenesis, clinical manifestations of lesions of the central and peripheral nervous system that have arisen or persist in patients in the postcoid period (Long-COVID-19). Their correct assessment, the use of effective methods of complex treatment, targeted neurorehabilitation contribute to the reversibility of functional disorders, prevention, reduction of disability, improvement of quality of life indicators, prevention of the progression of cognitive, emotional, behavioral disorders initiated by SARS-CoV-2.

About the authors

Vladimir V. Belopasov

Astrakhan State Medical University

Author for correspondence.
Email: belopasov@yandex.ru
ORCID iD: 0000-0003-0458-0703
SPIN-code: 6098-1321

Doctor of Medical Sciences, Professor, Head of the Department of Neurology and Neurosurgery with a course of postgraduate education 

Russian Federation, 121 Bakinskaya Street, Astrakhan 414000

Ekaterina N. Zhuravleva

Astrakhan State Medical University

Email: neurologKzh@rambler.ru
Russian Federation, 121 Bakinskaya Street, Astrakhan 414000

Natalia P. Nugmanova

Astrakhan State Medical University

Email: nanu@rambler.ru

MD, Cand. Sci (Med.)

Russian Federation, 121 Bakinskaya Street, Astrakhan 414000

Adela T. Abdrashitova

Astrakhan State Medical University

Email: adelia-79@yandex.ru
SPIN-code: 1820-0380

MD, Dr. Sci. (Med.)

Russian Federation, 121 Bakinskaya Street, Astrakhan 414000

References

  1. Yachou Y, El Idrissi A, Belopasov V, Benali SA. Neuroinvasion, neurotropic and neuroinflam-matory events of SARS-CoV-2: understanding the neurological manifestations in COVID-19 patients. Neurol Sci. 2020;41(10):2657-2669. doi: 10.1007/s10072-020-04575-3
  2. McGowan EM, Haddadi N, Nassif NT, Lin Y. Targeting the SphK-S1P-SIPR Pathway as a Potential Therapeutic Approach for COVID-19. Int J Mol Sci. 2020;21(19):7189. doi: 10.3390/ijms21197189
  3. Баклаушев В.П., Кулемзин С.В., Горчаков А.А., и др. COVID-19. Этиология, патогенез, диагностика и лечение // Клиническая практика. 2020. Т. 11, № 1. С. 7-20. [Baklaushev VP, Kulemzin SV, Gorchakov AA, et al. COVID-19. Etiology, pathogenesis, diagnosis and treatment. Journal of Clinical Practice. 2020;11(1):7-20. (In Russ).] doi: 10.17816/clinpract26339
  4. Белопасов В.В., Яшу Я., Самойлова Е.М., Баклаушев В.П. Поражение нервной системы при COVID-19 // Клиническая практика. 2020. Т. 11, № 2. С. 60-80. [Belopasov VV, Yashu Ya, Samoilova EM, Baklaushev VP. Lesion of the nervous system in COVID-19. Journal of Clinical Practice. 2020;11(2):60-80. (In Russ).] doi: 10.17816/clinpract34851
  5. Reza-Zaldfaar EE, Hernandez-Sapiens MA, Minjarez B, et al. Infection Mechanism of SARS-COV-2 and Its Implication on the Nervous System. Front Immunol. 2021;11:621735. doi: 10.3389/fimmu.2020.621735
  6. COVID-19 rapid guideline: managing the long-term effects of COVID-19. London: National Institute for Health and Care Excellence (UK); 2020.
  7. Garrigues E, Janvier P, Kherabi Y, et al. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. J Infect. 2020;81(6):e4-e6. doi: 10.1016/j.jinf.2020.08.029
  8. Yong SJ. Persistent brainstem dysfunction in long-COVID: a hypothesis. ACS Chem Neurosci. 2021;12(4):573-580. doi: 10.1021/acschemneuro.0c00793
  9. Taboada M, Carinena A, Moreno E, et al. Post-COVID-19 functional status six-months after hospitalization. J Infect. 2021;82(4):e31-e33. doi: 10.1016/j.jinf.2020.12.022
  10. Oronsky B, Larson C, Hammond TC, et al. A review of persistent post-COVID syndrome (PPCS). Clin Rev Allergy Immunol. 2021;1-9. doi: 10.1007/s12016-021-08848-3
  11. Garg P, Arora U, Kumar A, Wig N. The «post-COVID» syndrome: how deep is the damage? J Med Virol. 2021;93(2):673-674. doi: 10.1002/jmv.26465
  12. Iqbal A, Iqbal K, Arshad AS, et al. The COVID-19 sequelae: a cross-sectional evaluation of post-recovery symptoms and the need for rehabilitation of COVID-19 survivors. Cureus. 2021;13(2):e13080. doi: 10.7759/cureus.13080
  13. Moreno-Perez O, Merino E, Leon-Ramirez JM, et al. Post-acute COVID-19 syndrome. Incidence and risk factors: a mediterranean cohort study. J Infect. 2021;82(3):378-383. doi: 10.1016/j.jinf.2021.01.004
  14. Wijeratne T, Crewther S. COVID-19 and long-term neurological problems: Challenges ahead with Post-COVID-19 Neurological Syndrome. Aust J Gen Pract. 2021;(50). doi: 10.31128/AJGP-COVID-43
  15. Seyed AS, Afsahi AM, Mohsseni PM, et al. Late complications of COVID-19; a systematic review of current evidence. Arch Acad Emerg Med. 2021;9(1):e14. doi: 10.22037/aaem.v9i1.1058
  16. Nuzzo D, Cambula G, Bacile I, et al. Long-term brain disorders in post COVID-19 neurological syndrome (PCNS) patient. Brain Sci. 2021;11(4):454. doi: 10.3390/brainsci11040454
  17. Garci'a-Azorfn D, Trigo J, Talavera B, et al. Frequency and type of red flags in patients with COVID-19 and headache: a series of 104 hospitalized patients. Headache. 2020;60(8):1664-1672. doi: 10.1111/head.13927
  18. Bobker SM, Robbins MS. COVID19 and headache: a primer for trainees. Headache. J Head Face Pain. 2020;60(8):1806-1811. doi: 10.1111/head.13884
  19. Silva MT, Lima MA, Torezani G, et al. Isolated intracranial hypertension associated with COVID-19. Cephalalgia. 2020;40(13):1452-1458. doi: 10.1177/ 0333102420965-963
  20. Toptan T, Aktan С, Basar A, Bolay H. Case series of headache characteristics in COVID-19: headache can be an isolated symptom. Headache. 2020;60(8):1788-1792. doi: 10.1111/head.13940
  21. Karadas O, Ozturk B, Sonkaya AR, et al. Latent class cluster analysis identified hidden headache phenotypes in COVID-19: impact of pulmonary infiltration and IL-6. Neurol Sci. 2021;1-9. doi: 10.1007/s10072-020-04978-2
  22. Planchuelo-Gomez A, Trigo J, de Luis-Garci'a R, et al. Deep phenotyping of headache in hospitalized COVID-19 patients via principal component analysis. Front Neurol. 2020;11:583870. doi: 10.3389/fneur.2020.583870
  23. Al-Hashel JY, Ismail II. Impact of coronavirus disease 2019 (COVID-19) pandemic on patients with migraine: a webbased survey study. J Headache Pain. 2020;21(1):115. doi: 0.1186/s10194-020-01183-6
  24. Caronna E, Ballve A, Llaurado A, et al. Headache: A striking prodromal and persistent symptom, predictive of COVID-19 clinical evolution. Cephalalgia. 2020;40(13):1410-1421. doi: 10.1177/0333102420965157
  25. Poncet-Megemont L, Paris P, Tronchere A, et al. High prevalence of headaches during COVID-19 infection: a retrospective cohort study. Headache. 2020;60(10):2578-2582. doi: 10.1111/head.13923
  26. Badrah M, Riad A, Kassem I, et al. Craniofacial pain in COVID-19 patients with diabetes mellitus: Clinical and laboratory description of 21 cases. J Med Virol. 2021;93(5):2616-2619. doi: 10.1002/jmv.26866
  27. Szyszka-Sommerfeld L, Machoy M, Lipski M, Wozniak K. Electromyography as a means of assessing masticatory muscle activity in patients with pain-related temporomandibular disorders. Pain Res Manag. 2020;2020:9750915. doi: 10.1155/2020/9750915
  28. Lechien JR, Chiesa-Estomba CM, De Siati DR, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Otorhinolaryngol. 2020;277(8):2251-2261. doi: 10.1007/s00405-020-05965-1
  29. Veronese S, Sbarbati A. Chemosensory systems in COVID-19: evolution of scientific research. ACS Chem Neurosci. 2021;12(5):813-824. doi: 10.1021/acschemneuro.0c00788
  30. Lee Y, Min P, Lee S, Kim SW. Prevalence and duration of acute loss of smell or taste in COVID-19 patients. J Korean Med Sci. 2020;35(18):e174. doi: 10.3346/jkms.2020.35.e174
  31. Nguyen NN, Hoang VT, Lagier JC, et al. Long-term persistence of olfactory and gustatory disorders in COVID-19 patients. Clin Microbiol Infect. 2021;S1198-743X(20)30781-3. doi: 10.1016/j.cmi.2020.12.021
  32. Oliveira RM, Santos DH, Olivetti BC, Takahashi JT. Bilateral trochlear nerve palsy due to cerebral vasculitis related to COVID-19 infection. Arq Neuropsiquiatr. 2020;78(6):385-386. doi: 10.1590/0004-282X20200052
  33. Doblan A, Kaplama ME, Ak S, et al. Cranial nerve involvement in COVID-19. Am J Otolaryngol. 2021;42(5):102999. doi: 10.1016/j.amjoto.2021.102999
  34. Correa DG, Hygino da Cruz LC, Lopes FR, et al. Magnetic resonance imaging features of COVID-19-related cranial nerve lesions. J Neurovirol. 2021;27(1):171-177. doi: 10.1007/s13365-020-00934-0
  35. Decavel P, Petit C, Tatu L. Tapia syndrome at the time of the COVID-19 pandemic: Lower cranial neuropathy following prolonged intubation. Neurology. 2020;95(7):312-313. doi: 10.1212/WNL.0000000000010011
  36. Khacha A, Bouchal S, Ettabyaoui A, et al. Cavernous sinus thrombosis in a COVID-19 patient: A case report. Radiol Case Rep. 2021;16(3):480-482. doi: 10.1016/j.radcr.2020.12.013
  37. Katyal N, Narula N, Acharya S, Govindarajan R. Neuromuscular complications with SARS-Cov-2 infection: a review. Front Neurol. 2020;11:1052. doi: 10.3389/fneur.2020.01052
  38. Dos Santos Martins TG. Isolated post SARS-CoV-2 diplopia. J Neurol. 2021;268(2):391. doi: 10.1007/s00415-020-10072-6
  39. Cavalagli A, Peiti G, Conti C, et al. Cranial nerves impairment in post-acute oropharyngeal dysphagia after COVID-19. Eur J Phys Rehabil Med. 2020;56(6):853-857. doi: 10.23736/S1973-9087.20.06452-7
  40. Dicpinigaitis PV, Canning BJ. Is there (will there be) a post-COVID-19 chronic cough? Lung. 2020;198(6):863-865. doi: 10.1007/s00408-020-00406-6
  41. Visca D, Beghe B, Fabbri LM, et al. Management of chronic refractory cough in adults. Eur J Intern Med. 2020;81:15-21. doi: 10.1016/j.ejim.2020.09.008.
  42. Halpert G, Shoenfeld Y. SARS-CoV-2, the autoimmune virus. Autoimmun Rev. 2020;19(12):102695. doi: 10.1016/j.autrev.2020.102695
  43. Abu-Rumeileh S, Abdelhak A, Foschi M, et al. Guillain-Barre syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases. J Neurol. 2021;268(4):1133-1170. doi: 10.1007/s00415-020-10124-x
  44. Panariello A, Bassetti R, Radice A, et al. Anti-NMDA receptor encephalitis in a psychiatric COVID-19 patient: A case report. Brain Behav Immun. 2020;87:179-181. doi: 10.1016/j.bbi.2020.05.054
  45. Бойко А.Н., Сиверцева С.А., Спирин Н.Н. Поражение нервной системы при инфекции COVID-19 с акцентом на ведение пациентов с рассеянным склерозом // Неврология, нейропсихиатрия, психосоматика. 2020. Т. 12, № 1. С. 44-47. [Boyko AN, Sivertseva SA, Spirin NN. Lesion of the nervous system in COVID-19 infection with an emphasis on the management of patients with multiple sclerosis. Neurology, neuropsychiatry, psychosomatics. 2020;12(1):44-47. (In Russ).] doi: 10.14412/2074-2711-2020-1S-44-47
  46. Memon AB, Al-Hader R, Patel S, et al. Late-onset rapidly progressive MRI- negative-myelitis after COVID-19 illness. Clin Neurol Neurosurg. 2021;202:106513. doi: 10.1016/j.clin-euro.2021.106513
  47. Sansone P, Giaccari LG, Aurilio C, et al. Post-Infectious Guillain-Barre syndrome related to SARS-CoV-2 infection: a systematic review. Life (Basel). 2021;11(2):167. doi: 10.3390/life11020167
  48. Waheed S, Bayas A, Hindi F, et al. Neurological complications of COVID-19: guillain-barre syndrome following pfizer COVID-19 vaccine. Cureus. 2021;13(2):e13426. doi: 10.7759/cureus.13426
  49. Lunn MP, Cornblath DR, Jacobs BC, et al. COVID-19 vaccine and Guillain-Barre syndrome: let’s not leap to associations. J Brain. 2021;144(2):357-360. doi: 10.1093/brain/awaa444
  50. Гусев Е.И., Мартынов М.Ю., Бойко А.Н., и др. Новая коронавирусная инфекция (COVID-19) и поражение нервной системы: механизмы неврологических расстройств, клинические проявления, организация неврологической помощи // Журнал неврологии и психиатрии им. С.С. Корсакова. 2020. Т. 120, № 6. С. 7-16. [Gusev EI, Martynov MYu, Boyko AN, et al. New coronavirus infection (COVID-19) and damage to the nervous system: mechanisms of neurological disorders, clinical manifestations, organization of neurological care. Journal of Neurology and Psychiatry named after S.S. Korsakov. 2020;120(6):7-16. (In Russ).] doi: 10.17116/jnevro20201200617
  51. Avenali M, Martinelli D, Todisco M, et al. Clinical and electrophysiological outcome measures of patients with post-infectious neurological syndromes related to COVID-19 treated with intensive neurorehabilitation. Front Neurol. 2021;12:643713. doi: 10.3389/fneur.2021.643713
  52. Курушина О.В., Барулин А.Е. Поражение центральной нервной системы при COVID-19 // Журнал неврологии и психиатрии им. С.С. Корсакова. 2021. Т. 121, № 1. С. 92-97. [Kurushina OV, Barulin AE. Damage to the central nervous system in COVID-19. Journal of Neurology and Psychiatry named after S.S. Korsakov. 2021;121(1):92-97. (In Russ).]
  53. Tung-Chen Y, Blanco-Alonso S, Anton-Huguet B, et al. Dolor toracico persistente tras resolucion de la enfermedad por coronavirus 2019 (COVID-19). Semergen. 2020;46(Suppl 1):88-90. doi: 10.1016/j.semerg.2020.06.006
  54. Yousefzai R, Bhimaraj A. Misdiagnosis in the COVID-19 era: when zebras are everywhere, don’t forget the horses. JACC Case Rep. 2020;2(10):1614-1619. doi: 10.1016/j.jaccas.2020.04.018
  55. Poggiali E, Vercelli A, Demichele E, et al. Diaphragmatic rupture and gastric perforation in a patient with COVID-19 pneumonia. Eur J Case Rep Intern Med. 2020;7(6):001738. doi: 10.12890/2020_001738
  56. Newton-Cheh C, Zlotoff DA, Hung J, et al. Case 24-2020: a 44-year-old woman with chest pain, dyspnea, and shock. N Engl J Med. 2020;383(5):475-484. doi: 10.1056/NEJ-Mcpc2004975
  57. Gahide G, Frandon J, Vendrell JF. COVID-19 patients presenting with afebrile acute abdominal pain. Clin Med (Lond). 2020;20(3):e4-e6. doi: 10.7861/clinmed.2020-0150
  58. Ивашкин В.Т., Шептулин А.А., Зольникова О.Ю., и др. Новая коронавирусная инфекция (COVID-19) и система органов пищеварения // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020. Т. 30, № 3. С. 7-13. [Ivashkin VT, Sheptulin AA, Zolnikova OYu, et al. New coronavirus infection (COVID-19) and the digestive system. Russian Journal of Gastroenterology, Hepatology and Coloproctology. 2020;30(3):7-13. (In Russ).] doi: 10.22416/1382-4376-2020-30-3-7
  59. Коган Е.А., Березовский Ю.С., Проценко Д.Д., Багдасарян Т.Р. Патологическая анатомия инфекции, вызванной SARS-CoV-2 // Судебная медицина. 2020. Т. 6, № 2. С. 8-30. [Kogan EA, Berezovsky YuS, Protsenko DD, Bagdasaryan TR. Pathological anatomy of infection caused by SARS-CoV-2. Russian Journal of Forensic Medicine. 2020;6(2):8-30. (In Russ).] doi: 10.19048/2411-8729-2020-6-2-8-30
  60. Cheung S, Quiwa JC, Pillai A, et al. Superior mesenteric artery thrombosis and acute intestinal ischemia as a consequence of COVID-19 infection. Am J Case Rep. 2020;21:e925753. doi: 10.12659/AJCR.925753
  61. Widyadharma IP, Sari NN, Pradnyaswari KE, et al. Pain as clinical manifestations of COVID-19 infection and its management in the pandemic era: a literature review. Egypt J Neurol Psychiatr Neurosurg. 2020;56(1):121. doi: 10.1186/s41983-020-00258-0
  62. Weng LM, Su X, Wang XQ. Pain symptoms in patients with coronavirus disease (COVID-19): a literature review. J Pain Res. 2021;14:147-159. doi: 10.2147/JPR.S269206
  63. Clauw DJ, Hauser W, Cohen SP, Fitzcharles MA. Considering the potential for an increase in chronic pain after the COVID-19 pandemic. PAIN. 2020;161(8):1694-1697. doi: 10.1097/j.pain.0000000000-001950
  64. Aksan F, Nelson EA, Swedish KA. A COVID-19 patient with intense burning pain. J Neurovirol. 2020;26(5):800-801. doi: 10.1007/s13365-020-00887-4
  65. Attal N, Martinez V, Bouhassira D. Potential for increased prevalence of neuropathic pain after the COVID-19 pandemic. Pain Rep. 2021;6(1):e884. doi: 10.1097/PR9.000-0000000000884
  66. Meyer-FrieBem CH, Gierthmuhlen J, Baron R, et al. Pain during and after COVID-19 in Germany and worldwide: a narrative review of current knowledge. Pain Rep. 2021;6(1):e893. doi: 10.1097/ PR9.0000000000000893
  67. Alonso-Matielo H, da Silva Oliveira VR, de Oliveira VT, Dale CS. Pain in COVID era. Front Physiol. 2021;12:624154. doi: 10.3389/fphys.2021.624154
  68. Bureau BL, Obeidat A, Dhariwal MS, Jha P. Peripheral neuropathy as a complication of SARS-Cov-2. Cureus. 2020;12(11):e11452. doi: 10.7759/cureus.11452
  69. Fernandez CE, Franz CK, Ko JH, et al. Imaging review of peripheral nerve injuries in patients with COVID-19. Radiology. 2021;298(3):E117-E130. doi: 10.1148/radiol.202020-3116
  70. Andalib S, Biller J, Di Napoli M, et al. Peripheral nervous system manifestations associated with COVID-19. Curr Neurol Neurosci Rep. 2021;21(3):9. doi: 10.10-07/s11910-021-01102-5
  71. Sabharwal P, Chakraborty S, Tyagi N, Kumar A. Acute flaccid quadriparesis in a recovering COVID-19 patient: a clinical dilemma. Indian J Crit Care Med. 2021;25(2):238-239. doi: 10.5005/ jp-journals-10071-23728
  72. Карлов В.А., Бурд С.Г., Лебедева А.В., и др. Эпилепсия и COVID-19. Тактика и лечение. Рекомендации Российской противоэпилептической лиги // Эпилепсия и пароксизмальные состояния. 2020. Т. 12, № 1. С. 84-88. [Karlov VA, Burd SG, Lebedeva AV, et al. Epilepsy and COVID-19. Tactics and treatment. Recommendations of the Russian Antiepileptic League. Epilepsy and Paroxysmal States. 2020;12(1):84-88. (In Russ).]
  73. Danoun OA, Zillgitt A, Hill C, et al. Outcomes of seizures, status epilepticus, and EEG findings in critically ill pa-tient with COVID-19. Epilepsy Behav. 2021;118:107923. doi: 10.1016/j.yebeh.2021.107923
  74. Kincaid KJ, Kung JC, Senetar AJ, et al. Post-COVID seizure: A new feature of “long-COVID”. Eur Neur Sci. 2021;23:100340. doi: 10.1016/j.ensci.2021.100340
  75. Dono F, Nucera B, Lanzone J, et al. Status epilepticus and COVID-19: A systematic review. Epilepsy Behav. 2021;118:107887. doi: 10.1016/j.yebeh.2021.107887
  76. Belli S, Balbi B, Prince I, et al. Low physical functioning and impaired performance of activities of daily life in COVID-19 patients who survived the hospitalisation. Eur Respir J. 2020;56(4):2002096. doi: 10.1183/13993003.02096-2020
  77. Mohr A, Dannerbeck L, Lange TJ, et al. Cardiopulmonary exercise pattern in patients with persistent dyspnoea after recovery from COVID-19. Respir Med. 2021;16(1):732. doi: 10.4081/mrm.2021.732
  78. Townsend L, Dyer AH, Jones K, et al. Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. PLoS One. 2020;15(11):e0240784. doi: 10.1371/journal.pone.0240784
  79. Roy D, Ghosh R, Dubey S, et al. Neurological and neuropsychiatric impacts of COVID-19 pandemic. Can J Neurol Sci. 2021;48(1):9-24. doi: 10.1017/cjn.2020.173
  80. Tuzun S, Keles A, Okutan D, et al. Assessment of musculoskeletal pain, fatigue and grip strength in hospitalized patients with COVID-19. Eur J Phys Rehabil Med. 2021. doi: 10.23736/S1973-9087.20.06563-6
  81. Ortelli P, Ferrazzoli D, Sebastianelli L, et al. Neuropsychological and neurophysiological correlates of fatigue in post-acute patients with neurological manifestations of COVID-19: Insights into a challenging symptom. J Neurol Sci. 2021;420:117271. doi: 10.1016/j.jns.2020.117271
  82. Mohabbat AB, Mohabbat NM, Wight EC. Fibromyalgia and chronic fatigue syndrome in the age of COVID-19. Mayo Clin Proc Innov Qual Outcomes. 2020;4(6):764-766. doi: 10.1016/j.mayocpiqo.2020.08.002
  83. Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020;94:91-95. doi: 10.1016/j.ijid.2020.03.017
  84. Ferraro F, Calafiore D, Dambruoso F, et al. COVID-19 related fatigue: Which role for rehabilitation in post-COVID-19 patients? A case series. J Med Virol. 2021;93(4):1896-1899. doi: 10.1002/jmv.26717
  85. Miners S, Kehoe PG, Love S. Cognitive impact of COVID-19: looking beyond the short term. Alzheimers Res Ther. 2020;12(1):170. doi: 10.1186/s13195-020-00744-w
  86. Guedj E, Million M, Dudouet P, et al. (18)F-FDG brain PET hypometabolism in post-SARS-CoV-2 infection: substrate for persistent/delayed disorders? Eur J Nucl Med Mol Imaging. 2021;48(2):592-595. doi: 10.1007/s00259-020-04973-x
  87. Whiteside DM, Oleynick V, Holker E, et al. Neurocognitive deficits in severe COVID-19 infection: Case series and proposed model. Clin Neuropsychol. 2021;1-20. doi: 10.1080/13854046.2021.1874056
  88. Stracciari A, Bottini G, Guarino M,; Cognitive and Behavioral Neurology Study Group of the Italian Neurological Society. Cognitive and behavioral manifestations in SARS-CoV-2 infection: not specific or distinctive features? Neurol Sci. 2021;1-9. doi: 10.1007/s10072-021-05231-0
  89. Остроумова Т.М., Черноусов П.А., Кузнецов И.В. Когнитивные нарушения у пациентов, перенесших COVID-19 // Неврология, нейропсихиатрия, психосоматика. 2021;13(1):126-130. [Ostroumova TM, Chernousov PA, Kuznetsov IV. Cognitive disorders in patients who underwent COVID-19. Neurology, neuropsychiatry, psychosomatics. 2021;13(1):126-130. (In Russ).] doi: 10.14412/2074-2711-2021-1-126-130
  90. Alemanno F, Houdayer E, Parma A, et al. COVID-19 cognitive deficits after respiratory assistance in the subacute phase: A COVID-rehabilitation unit experience. PLoS One. 2021;16(2):e0246590. doi: 10.1371/journal. pone.0246590
  91. Pajo AT, Espiritu AI, Apor AD, Jamora RD. Neuropathologic findings of patients with COVID-19: a systematic review. Neurol Sci. 2021;1-12. doi: 10.1007/s10072-021-05068-7
  92. Paterson RW, Brown RL, Benjamin L, et al. The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings. Brain. 2020;143(10):3104-3120. doi: 10.1093/brain/awaa240
  93. Струментова Е.С., Лобзин В.Ю., Лобзин С.В. Нарушение обоняния, поражение центральной нервной системы и риск развития нейродегенеративных заболеваний при COVID-19//Opinion Leader. 2020. № 8. С. 28-34. [Strumentova ES, Lobzin VYu, Lobzin SV. Olfactory impairment, central nervous system damage and risk of neurodegenerative diseases in COVID-19. Opinion Leader. 2020;(8):28-34. (In Russ).]
  94. El Bini Dhouib I. Does coronaviruses induce neurodegener-ative diseases? A systematic review on the neurotropism and neuroinvasion of SARS-CoV-2. Drug Discov Ther. 2021;14(6):262-272. doi: 10.5582/ddt.2020.03106
  95. Steardo L, Steardo L, Verkhratsky A. Psychiatric face of COVID-19. Transl Psychiatry. 2020;10(1):261. doi: 10.1038/s41398-020-00949-5
  96. Новикова Л.Б., Акопян А.П., Шарапова К.М., Латыпова Р.Ф. Неврологические и психические расстройства, ассоциированные с COVID 19 // Артериальная гипертензия. 2020. Т. 26, № 3. Р. 317-326. [Novikova LB, Akopyan AP, Sharapova KM, Latypova RF. Neurological and mental disorders associated with COVID 19. Arterial Hypertension. 2020;26(3):317-326. (In Russ).] doi: 10.18705/1607-419X-2020-26-3-317-326
  97. Jasti M, Nalleballe K, Dandu V, Onteddu S. A review of pathophysiology and neuropsychiatric manifestations of COVID-19. J Neurol. 2020;1-6. doi: 10.1007/s00415-020-09950-w
  98. Rogers JP, David AS. A longer look at COVID-19 and neuropsychiatric outcomes. Lancet Psychiatry. 2021;8(5):351-352. doi: 10.1016/S2215-0366(21)00120-6
  99. Rogers JP, Chesney E, Oliver D, et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry. 2020;7(7):611-627. doi: 10.1016/S2215-0366(20)30203-0
  100. Харламенкова Н.Е., Быховец Ю.В., Дан М.В., Никитина Д.А. Переживание неопределенности, тревоги, беспокойства в условиях COVID-19 // Психологический журнал. 2020. [Kharlamenkova NE, Bykhovets YuV, Dan MV, Nikitina DA. Experiencing uncertainty, anxiety, and anxiety in the conditions of COVID-19. Psychological Journal. 2020. (In Russ).] Режим доступа: http://ipras.ru/cntnt/rus/institut_p/covid-19/kommentarii-eksp/har-1.html. Дата обращения: 15.03.2021.
  101. Дороженок И.Ю. Депрессии в период пандемии COVID-19 (разборы клинических случаев) // Неврология, нейропсихиатрия, психосоматика. 2021;13(1):81-86. [Dorozhe-nok IYu. Depression during the COVID-19 pandemic (analysis of clinical cases). Neurology, neuropsychiatry, psychosomatics. 2021;13(1):81-86. (In Russ).] doi: 10.14412/2074-2711-2021-1-81-86
  102. ijlek A, Bale MK. Phantosmia with COVID-19 related olfactory dysfunction: report of nine case. Indian J Otolaryngol Head Neck Surg. 2021;1-3. doi: 10.1007/s12070-021-02505-z
  103. Liu DT, Sabha M, Damm M, et al. Parosmia is associated with relevant olfactory recovery after olfactory training. Laryngoscope. 2021;131(3):618-623. doi: 10.1002/lary.29277
  104. Fontana IC, Bongarzone S, Gee A, et al. PET Imaging as a tool for assessing COVID-19 brain changes. Trends Neurosci. 2020;43(12):935-938. doi: 10.1016/ j.tins.2020.10.010
  105. Al-Sarraj S, Troakes C, Hanley B, et al. Invited review: the spectrum of neuropathology in COVID-19. Neuropathol Appl Neurobiol. 2021;47(1):3-16. doi: 10.1111/nan.12667
  106. Belli S, Balbi B, Prince I, et al. Low physical functioning and impaired performance of activities of daily life in COVID-19 patients who survived the hospitalisation. Eur Respir J. 2020;56(4):2002096. doi: 10.1183/13993003.02096-2020
  107. Goodman BP, Khoury JA, Blair JE, Grill MF. COVID-19 dysautonomia. Front Neurol. 2021;12:624968. doi: 10.3389/fneur.2021.624968
  108. Johansson M, Stahlberg M, Runold M, et al. Long-haul post-COVID-19 symptoms presenting as a variant of postural orthostatic tachycardia syndrome: the swedish experience. JACC Case Rep. 2021. doi: 10.1016/j.jaccas.2021.01.009
  109. Blitshteyn S, Whitelaw S. Postural orthostatic tachycardia syndrome (POTS) and other autonomic disorders after COVID-19 infection: a case series of 20 patients. Immunol Res. 2021;1-6. doi: 10.1007/s12026-021-09185-5
  110. Motiejunaite J, Balagny P, Arnoult F, et al. Hyperventilation: a possible explanation for long-lasting exercise intolerance in mild COVID-19 survivors? Front Physiol. 2021;11:614590. doi: 10.3389/fphys.2020.614590
  111. Pasquetto G, Conti GB, Susana A, et al. Syncope, Brugada syndrome, and COVID-19 lung disease. J Arrhythm. 2020;36(4):768-770. doi: 10.1002/joa3.12375
  112. Doodnauth AV, Jallad A, Rizk D, et al. Syncope associated with sinus nodal dysfunction in a COVID-19 patient: a case report and review of the literature. Am J Med Case Rep. 2021;9(4):263-267. doi: 10.12691/ajmcr-9-4-15
  113. Oates CP, Turagam MK, Musikantow D, et al. Syncope and presyncope in patients with COVID-19. Pacing Clin Electrophysiol. 2020;43(10):1139-1148. doi: 10.1111/pace.14047
  114. Hernandez PI, Talavera de la EB, Valle PG, Garci'a AD. Isolated syncope as a form of presentation of COVID-19 infection. Neu-rologia. 2021;36(2):185-187. doi: 10.1016/j.nrl.2020.11.001
  115. Birlutiu V, Birlutiu RM, Feiereisz AI. SARS-CoV-2 infection associated with micturition syncope: Our experience with 4 case reports. Medicine (Baltimore). 2020;99(31):e21512. doi: 10.1097/MD.0000000000021512
  116. Singh S, Desai R, Gandhi Z, et al. Takotsubo syndrome in patients with COVID-19: a systematic review of published cases. SN Compr Clin Med. 2020;1-7. doi: 10.1007/s42399-020-00557-w
  117. Finsterer J, Stollberger C. SARS-CoV-2 associated polyradiculitis and myocarditis may favour Takotsubo syndrome. Med Hypotheses. 2021;148:110509. doi: 10.1016/j.mehy.2021. 110-509
  118. Tan GP, Ho S, Fan BE, et al. Reversible platypnea-orth-odeoxia in COVID-19 acute respiratory distress syndrome survivors. Respir Physiol Neurobiol. 2020;282:3510-3515. doi: 10.1016/j.resp.2020.103515
  119. Singh K, Kadnur H, Ray A, et al. Platypnea-orthodeoxia in a patient with severe COVID-19 pneumonia. Arch Chest Dis. 2020;90(4). doi: 10.4081/monal-di.2020.1609
  120. Novak P. Post COVID-19 syndrome associated with orthostatic cerebral hypoperfusion syndrome, small fiber neuropathy and benefit of immunotherapy: a case report. Eur Neur Sci. 2020;21:100276. doi: 10.1016/j.ensci.2020.100276
  121. Chigr F, Merzouki M, Najimi M. Autonomic brain centers and pathophysiology of COVID-19. ACS Chem Neurosci. 2020;11:1520-1522. doi: 10.1021/acschemneuro.0c00265
  122. Dani M, Dirksen A, Taraborrelli P, et al. Autonomic dysfunction in ‘long COVID’: rationale, physiology and management strategies. Clin Med (Lond). 2021;21(1):e63-e67. doi: 10.7861/clinmed.2020-0896
  123. Трошина Е.А., Мельниченко Г.А., Сенюшкина Е.С., Мокрышева Н.Г. Адаптация гипоталамо-гипофизарно-тиреоидной и гипоталамо-гипофизарно-надпочечниковой систем к новому инфекционному заболеванию — COVID-19 в условиях развития COVID-19-пневмонии и/или цитокинового шторма // Клиническая и экспериментальная тиреоидология. 2020. Т. 16, № 1. С. 21-27. [Troshina EA, Melnichenko GA, Seny-ushkina ES, Mokrysheva NG. Adaptation of the hypothalamic-pituitary-thyroid and hypothalamic-pituitary-adrenal systems to a new infectious disease-COVID-19 in the development of COVID-19-pneumonia and/or cytokine storm. Clinical and Experimental Thyroidol-ogy. 2020;16(1):21-27. (In Russ).] doi: 10.14341/ket12461
  124. De Gennaro R, Gastaldo E, Tamborino C, et al. Selective cranial multineuritis in severe COVID-19 pneumonia: two cases and literature review. Neurol Sci. 2021;42(5):1643-1648. doi: 10.1007/s10072-021-05087-4
  125. Kaya Tutar N, Kale N, Tugcu B. Adie-holmes syndrome associated with COVID-19 infection: a case report. Indian J Ophthalmol. 2021;69(3):773-774. doi: 10.4103/ijo.IJO_3589_20
  126. Alzahrani AS, Mukhtar N, Aljomaiah A, et al. The impact of COVID-19 viral infection on the hypothalamic-pituitary-adrenal axis. Endocr Pract. 2021;27(2):83-89. doi: 10.1016/j.eprac.2020.10.014
  127. Kothandaraman N, Rengaraj A, Xue B, et al. COVID-19 en-docrinopathy with hindsight from SARS. Am J Physiol Endocrinol Metab. 2021;320(1):E139-E150. doi: 10.1152/ajpendo.00480.2020
  128. Tajlidere B, Mehmetaj L, Ozcan AB, et al. Melkersson-Rosenthal syndrome induced by COVID-19. Am J Emerg Med. 2021;41:262.e5-262.e7. doi: 10.1016/j.ajem.2020.08.018
  129. Ahmed O, Aladham Y, Mahmood S, Abdelnaby MM. Complicated sinusitis with sphenopalatine artery thrombosis in a COVID-19 patient: a case report. J Surg Case Rep. 2021;2021(3):rjab010. doi: 10.1093/jscr/rjab010
  130. Gherlone EF, Polizzi E, Tete G, et al. Frequent and persistent salivary gland ectasia and oral disease after COVID-19. J Dent Res. 2021;100(5):464-471. doi: 10.1177/002203452-1997112
  131. Katz J. Prevalence of dry mouth in COVID-19 patients with and without Sicca syndrome in a large hospital center. Ir J Med Sci. 2021;1-3. doi: 10.1007/s11845-020-02480-4
  132. Пушкина Н.В. Алопеции и COVID-19. Варианты ведения трихологических пациентов // Косметика и медицина. 2021. № 1. С. 134-140. [Pushkina NV. Alopecia and COVID-19. Options for the management of trichological patients. Cosmetics and Medicine. 2021;(1):134-140. (In Russ).]
  133. Meyer C, Haustrate MA, Nisolle JF, Deltombe T. Heterotopic ossification in COVID-19: a series of 4 cases. Ann Phys Rehabil Med. 2020;63(6):565-567. doi: 10.1016/j.rehab.2020.09.010
  134. Barker-Davies RM, O’Sullivan O, Senaratne KP, et al. The Stanford Hall consensus statement for post-COVID-19 rehabilitation. Br J Sports Med. 2020;54(16):949-959. doi: 10.1136/bjsports-2020-102596
  135. Putko RM, Bedrin MD, Clark DM, et al. SARS-CoV-2 and limb ischemia: a systematic review. J Clin Orthop Trauma. 2021;12(1):194-199. doi: 10.1016/j.jcot.2020.11.018
  136. Ramondetta A, Ribero S, Costi S, Dapavo P. Pression-induced facial ulcers by prone position for COVID-19 mechanical ventilation. Dermatol Ther. 2020;33(4):e13748. doi:10.1111dth.13-748
  137. Yu JN, Wu BB, Feng LP, Chen HL. COVID-19 related pressure injuries in patients and personnel: A systematic review. J Tissue Viability. 2021;S0965-206X(21)00040-1. doi: 10.1016/j.jtv.2021.04.002
  138. Pauli MA, Pereira LM, Monteiro ML, et al. Painful palatal lesion in a patient with COVID-19. Oral Surg Oral Med Oral Pathol Oral Radiol. 2021;S2212-4403(21)00160-7. doi: 10.1016/j.oooo.2021.03.010
  139. Ramani SL, Samet J, Franz CK, et al. Musculoskeletal involvement of COVID-19: review of imaging. Skeletal Radiol. 2021;1-11. doi: 10.1007/s00256-021-03734-7
  140. Bax F, Lettieri C, Marini A, et al. Clinical and neurophysiological characterization of muscular weakness in severe COVID-19. Neurol Sci. 2021;1-6. doi: 10.1007/s10072-021-05110-8
  141. Mehan WA, Yoon BC, Lang M, et al. Paraspinal myositis in patients with COVID-19 Infection. AJNR Am J Neuroradiol. 2020;41(10):1949-1952. doi: 10.3174/ajnr.A6711
  142. Theodorou DJ, Theodorou SJ, Axiotis A, et al. COVID-19 vaccine-related myositis. QJM. 2021;hcab043. doi: 10.1093/qjmed/hcab04
  143. Barp A, Velardo D, Ciscato P, et al. Anti-HMGCR myopathy misdiagnosed as motor neuron disease and complicated with COVID-19 infection. Neurol Sci. 2021;1-4. doi: 10.1007/s10072-021-05146-w
  144. Quintana-Ortega C, Remesal A, Ruiz de Valbuena M, et al. Fatal outcome of anti-MDA5 juvenile dermatomyositis in a paediatric COVID-19 patient: a case report. Mod Rheumatol Case Rep. 2021;5(1):101-107. doi: 10.1080/24725625.2020.1832755
  145. Nasuelli NA, Pettinaroli R, Godi L, et al. Critical illness neuromyopathy (CINM) and focal amyotrophy in intensive care unit (ICU) patients with SARS-CoV-2: a case series. Neurol Sci. 2021;42(3):1119-1121. doi: 10.1007/s10072-020-04820-9
  146. Manzano GS, Woods JK, Amato AA. COVID-19-associated myopathy caused by type I interferonopathy. N Engl J Med. 2020;383(24):2389-2390. doi: 10.1056/NEJMc2031085
  147. Van Aerde N, van den Berghe G, Wilmer A, et al. Intensive care unit acquired muscle weakness in COVID-19 patients. Intensive Care Med. 2020;46(11):2083-2085. doi: 10.1007/s00134-020-06244-7
  148. Mendez-Guerrero A, Laespada-Garci'a MI, Gomez-Grande A, et al. Acute hypokinetic-rigid syndrome following SARS-CoV-2 infection. J Neurology. 2020;95(15):e2109-e2118. doi: 10.12-12/WNL.0000000000010282
  149. Roy D, Song J, Awad N, Zamudio P. Treatment of unexplained coma and hypokinetic-rigid syndrome in a patient with COVID-19. BMJ Case Rep. 2021;14(3):e239781. doi: 10.1136/bcr-2020-239781
  150. Diezma-Martfn AM, Morales-Casado MI, Garca-Al-varado N, et al. Tremor and ataxia in COVID-19. Neurologia. 2020;35(6):409-410. doi: 10.1016/j.nri.2020.06.005
  151. Chan JL, Murphy KA, Sarna JR. Myoclonus and cerebellar ataxia associated with COVID-19: a case report and systematic review. J Neurol. 2021;1-32. doi: 10.1007/s00415-021-10458-0
  152. Cohen ME, Eichel R, Steiner-Birmanns B, et al. A case of probable Parkinson’s disease after SARS-CoV-2 infection. Lancet Neurol. 2020;19(10):804-805. doi: 10.1016/S1474-4422(20)30305-7
  153. Brundin P, Nath A, Beckham JD. Is COVID-19 a perfect storm for Parkinson’s disease? Trends Neurosci. 2020;43(12):931-933. doi: 10.1016/j.tins.2020.10.009
  154. Wang H, Qin R, Zhang J, Chen Y. Possible immunity, inflammation, and oxidative stress mechanisms of Alzheimer>s disease in COVID-19 patients. Clin Neurol Neurosurg. 2021;201:106414. doi: 10.1016/j.clineuro.2020.106414
  155. Antonini A, Leta V, Teo J, Chaudhuri KR. Outcome of Parkinson>s disease patients affected by COVID-19. Mov Disord. 2020;35(6):905-908. doi: 10.1002/mds.28104
  156. Воробьев С.В., Шалепо К.В., Спасибова Е.В., и др. Инфекционные агенты как фактор риска развития болезни Альцгеймера // Журнал инфектологии. 2020. Т. 12, № 1. С. 5-13. [Vorobyov SV, Shalepo KV, Spasibova EV, et al. Infectious agents as a risk factor for the development of Alzheimer>s disease. Journal of Infectology. 2020;12(1):5-13. (In Russ).] doi: 10.22625/2072-6732-2020-12-1-5-13
  157. Yu Y, Travaglio M, Popovic R, et al. Alzheimer’s and Parkinson’s diseases predict different COVID-19 outcomes: a uk biobank study. Geriatrics (Basel). 2021;6(1):10. doi: 10.3390/geriat-rics6010010
  158. Borah P, Deb PK, Chandrasekaran B, et al. Neurological consequences of SARS-CoV-2 infection and concurrence of treatment-induced neuropsychiatric adverse events in COVID-19 patients: navigating the uncharted. Front Mol Biosci. 2021;8:627723. doi: 10.3389/fmolb.2021.627723
  159. Saniasiaya J, Kulasegarah J. Auditory cinchonism in COVID era. Ear Nose Throat J. 2020;99(9):597-598. doi: 10.1177/0145561320947255
  160. Al-Ramadan A, Rabab’h O, Shah J, Gharaibeh A. Acute and post-acute neurological complications of COVID-19. Neurol Int. 2021;13(1):102-119. doi: 10.3390/neurolint13010010
  161. Chang WT, Toh HS, Liao CT, Yu WL. Cardiac involvement of COVID-19: a comprehensive review. Am J Med Sci. 2021;361(1):14-22. doi: 10.1016/j.amjms.2020.10.002
  162. See I, Su JR, Lale A, et al. US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26. COV2.S; Vaccination, March 2 to, 2021. JAMA. 2021;e217517. doi: 10.1001/jama.2021.7517
  163. Wolf ME, Luz B, Niehaus L, et al. Thrombocytopenia and intracranial venous sinus thrombosis after “COVID-19 Vaccine AstraZeneca” exposure. J Clin Med. 2021;10(8):1599. doi: 10.3390/jcm10081599
  164. Roman GC, Gracia F, Torres A, et al. Acute transverse myelitis (ATM): clinical review of 43 patients with COVID-19-associated ATM and 3 post-vaccination ATM serious adverse events with the ChAdOx1 nCoV-19 vaccine (AZD1222). Front Immunol. 2021;12:653786. doi: 10.3389/fimmu.2021.653786
  165. Waheed S, Bayas A, Hindi F, et al. Neurological complications of COVID-19: Guillain-Barre syndrome following Pfizer COVID-19 vaccine. Cureus. 2021;13(2):e13426. doi: 10.7759/cureus.13426.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Arterio-arterial cerebral embolism of basial artery branches. Right-side hemi-syndrome of the brainstem, cerebellum. Asymmetric infarctions of occipital lobes.

Download (368KB)
Indexing metadata
3. Fig. 2. Malignant edematous Graves’ exophthalmos. Chemosis, ophthalmoplegia.

Download (296KB)
Indexing metadata

Copyright (c) 2021 Belopasov V.V., Zhuravleva E.N., Nugmanova N.P., Abdrashitova A.T.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies